Improved Pain Control in Terminally Ill Cancer Patients by Introducing Low-Dose Oral Methadone in Addition to Ongoing Opioid Treatment
- 1 February 2018
- journal article
- research article
- Published by SAGE Publications in Journal of Palliative Medicine
- Vol. 21 (2) , 177-181
Abstract
Background: Cancer pain is often not well controlled and there is a need for improved treatment strategies. Methadone exhibits unique properties among opioids and recent reports show promising results from adding a low dose of methadone to regular opioid therapy. Objective: To examine the effects of oral low-dose methadone added to regular scheduled opioids in terminally ill patients with complex cancer-related pain. Design: This was a retrospective chart review. Setting/Subjects: All patients with advanced cancer treated in a specialized palliative care unit who had received oral methadone in addition to another regular opioid were identified. Measurements: Intensity of pain, opioid doses, and occurrence of sedation, delirium, and respiratory depression were obtained from the patients' medical records for a period of one week after initiation of methadone. Results: Eighty patients were included. The median daily methadone dose was 10 mg during the treatment period. Eighty percent of the patients had improved pain control (p < 0.001). There was an increased risk for sedation and delirium, most pronounced in patients living 14 days or less after the start of methadone. No patient experienced respiratory depression. Conclusion: Addition of low-dose oral methadone to regular high-dose opioid treatment in cancer patients with complex pain close to death improves pain control, but also increases the risk for sedation and delirium.Keywords
This publication has 20 references indexed in Scilit:
- Update on Prevalence of Pain in Patients With Cancer: Systematic Review and Meta-AnalysisJournal of Pain and Symptom Management, 2016
- Cancer pain physiologyBritish Journal of Pain, 2014
- Addition of Methadone to Another Opioid in the Management of Moderate to Severe Cancer Pain: A Case SeriesJournal of Palliative Medicine, 2013
- Neuropathic cancer pain: Prevalence, severity, analgesics and impact from the European Palliative Care Research Collaborative–Computerised Symptom Assessment studyPalliative Medicine, 2012
- Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPCThe Lancet Oncology, 2012
- Use of Methadone as a CoanalgesicJournal of Pain and Symptom Management, 2011
- Treatment of cancer painThe Lancet, 2011
- Cooperative N-methyl-d-aspartate (NMDA) receptor antagonism and μ-opioid receptor agonism mediate the methadone inhibition of the spinal neuron pain-related hyperactivity in a rat model of neuropathic painPharmacological Research, 2009
- Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administrationSupportive Care in Cancer, 2001
- The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusionsPain, 1990